In AI for science, the true competitive advantage lies in generating unique, high-quality experimental data from self-driving labs. The AI models themselves are becoming commoditized, while the physical data remains the defensible asset.

Pacesa argues that closed-source models won't significantly outperform open-source tools because most rely on the same public PDB data. The true competitive advantage lies not in tweaking algorithms but in generating massive, proprietary, high-quality experimental datasets that can train genuinely superior models.

Public internet data has been largely exhausted for training AI models. The real competitive advantage and source for next-generation, specialized AI will be the vast, untapped reservoirs of proprietary data locked inside corporations, like R&D data from pharmaceutical or semiconductor companies.

Since LLMs are commodities, sustainable competitive advantage in AI comes from leveraging proprietary data and unique business processes that competitors cannot replicate. Companies must focus on building AI that understands their specific "secret sauce."

Xaira's core strategy involves creating massive, proprietary datasets that reveal causal biology. By systematically perturbing every gene in a cell to observe its effects, they generate unique training data for their models, quadrupling the world's supply of such information with a single publication.

A new 'Tech Bio' model inverts traditional biotech by first building a novel, highly structured database designed for AI analysis. Only after this computational foundation is built do they use it to identify therapeutic targets, creating a data-first moat before any lab work begins.

The key advantage for AI biotech isn't the model itself, but generating massive, proprietary datasets ("science tokens") via automated labs. This novel data, which doesn't exist publicly, is crucial for training superior models and achieving true scientific intelligence.

Algorithmic improvements alone are not enough for a new AI lab to challenge incumbents, who are also researching next-gen architectures. The only viable path is to focus on domains where proprietary data can be generated and is unavailable to the big labs, such as robotics or specialized life sciences.

The competitive advantage in pharma isn't the sophistication of an AI algorithm, which is often a commodity built on third-party models. The true differentiator is the quality, relevance, and end-to-end consistency of the proprietary data used to train and validate these models. Poor data invalidates even the best analytics.